Exclusive agreement covers 13 Central and Eastern European marketsCollaboration will help expand access to VANFLYTA for ...
Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...
Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...
In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...
Daiichi Sankyo and GENESIS Pharma will distribute and commercialize quizartinib, brand name VANFLYTA, in 13 markets.
DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or ...
A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback